LONDON--(BUSINESS WIRE)--NextPharma is pleased to announce that the US Food and Drug Administration (FDA) has completed a successful inspection of NextPharma’s centre of excellence for hormonal drug development and manufacturing in Waltrop, Germany. The inspection confirmed the site to be compliant with the principles and guidelines of Good Manufacturing Practice (GMP), and no Form 483 observations were issued. The US FDA authorities inspected the facility from 20th to 24th January, 2014 having originally inspected and approved the site in 2008.
Help employers find you! Check out all the jobs and post your resume.
